Biotech | March 14, 2022
Clarivate deals report highlights emerging trends in biopharma deal-making
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
The award recognizes and supports promising women scientists
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Subscribe To Our Newsletter & Stay Updated
